While the emerging biotech highlighted in today’s article is still in the early stages of developing a COVID-19 vaccine, the author advises that it “has significant advantages over other pure-play vaccine players” – and even if its COVID vaccine candidate is not ultimately successful, the firm has other promising vaccine candidates in its pipeline, including ones for hepatitis B and glioblastoma, the most aggressive type of brain cancer. For more on this small-cap stock that biotech investors may want to consider purchasing a stake in, CLICK HERE.